BPH care is advancing
With better-informed patients, dialogue becomes a cornerstone of treatment selection.
The treatment selection paradigm in BPH is evolving
However, as new options become available and patients seek to be more involved in the decision-making process, is there a need for a shift in the treatment selection paradigm?
“it is important to discuss the whole range of options available to them. We have a duty to do this…
It is our responsibility to encourage a two-way dialogue with our patients to understand the right treatment for them at that given time.”
A versatile portfolio that can meet your patients’ needs3–9
Each individual has diﬀerent priorities in improving their current quality of life.
They also oﬀer technical agility, allowing you to adapt to your patient’s needs and reach a shared treatment decision based on their prostate anatomy and potential clinical comorbidities.
So far, over a million patients have been treated with the Boston Scientiﬁc BPH treatment portfolio across clinical trials, observational studies, and clinical practice.5,9–13,17–19
The short hospital stay and overall cost saving provided by our portfolio can also aid in eﬃcient resource management for hospitals.12,14,20,21